Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2015

Open Access 01-12-2015 | Review

Immunogenicity of infectious pathogens and vaccine antigens

Authors: Siddhartha Mahanty, Antoine Prigent, Olivier Garraud

Published in: BMC Immunology | Issue 1/2015

Login to get access

Abstract

The concept of the immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. However, the theoretical notion of immunogenicity as discussed in older textbooks of immunology needs reconsideration due to advances in our understanding of immunologic responses. Immunogenicity is a property that can either be a desirable attribute, for example in the generation of an effective protective immunity against infectious pathogens or an undesirable trait, for example when it relates to novel therapeutic compounds and drugs, where an immune response needs to be prevented or inhibited. In this Forum Article, we aimed to revisit the issue of immunogenicity to discuss a series of simple questions relevant to the concept that are frequently rephrased but incompletely resolved in the immunologic literature.
Literature
1.
Murphy KTPWMJC. Janeway's immunobiology. New York: Garland Science; 2012.
2.
Anonymous. The American Heritage medical dictionary. Boston: Houghton Mifflin Co.; 2007.
3.
Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617–28.CrossRefPubMed
4.
Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247(1):52–63.CrossRefPubMed
5.
Butler NS, Harris TH, Blader IJ. Regulation of immunopathogenesis during Plasmodium and Toxoplasma infections: more parallels than distinctions? Trends Parasitol. 2013;29(12):593–602.CrossRefPubMed
6.
Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine. 2013;31(5):735–49.CrossRefPubMed
7.
Desombere I, Willems A, Gijbels Y, Leroux-Roels G. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen. J Virol. 2006;80(7):3506–14.CrossRefPubMedCentralPubMed
8.
Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 2011;7(9):e1002200.CrossRefPubMedCentralPubMed
9.
Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clinical research ed). 2014;349:g4643.
10.
Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013;10(7):400–10.CrossRefPubMed
11.
Glass RI, Parashar U, Patel M, Gentsch J, Jiang B. Rotavirus vaccines: successes and challenges. J Infect. 2014;68 Suppl 1:S9–18.CrossRefPubMed
12.
13.
14.
Mabbott NA. Prospects for safe and effective vaccines against prion diseases. Expert Rev Vaccines. 2014;1–4.
15.
Galson JD, Pollard AJ, Trück J, Kelly DF. Studying the antibody repertoire after vaccination: practical applications. Trends Immunol. 2014;35(7):319–31.CrossRefPubMed
16.
Gras S, Burrows SR, Turner SJ, Sewell AK, McCluskey J, Rossjohn J. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev. 2012;250(1):61–81.CrossRefPubMed
17.
Busch R, De Riva A, Hadjinicolaou AV, Jiang W, Hou T, Mellins ED. On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev Mol Med. 2012;14, e15.CrossRefPubMedCentralPubMed
18.
Shastri N, Nagarajan N, Lind KC, Kanaseki T. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. Curr Opin Immunol. 2014;26:123–7.CrossRefPubMed
19.
Thaunat O. Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol. 2012;26(2-3):101–6.CrossRefPubMed
20.
Malik B, Rath G, Goyal AK. Are the anatomical sites for vaccine administration selected judiciously? Int Immunopharmacol. 2014;19(1):17–26.CrossRefPubMed
21.
Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012;30(2):142–54.CrossRefPubMed
22.
Kraehenbuhl JP, Neutra MR. Mucosal vaccines: where do we stand? Curr Top Med Chem. 2013;13(20):2609–28.CrossRefPubMed
23.
Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012;33(6):297–305.CrossRefPubMed
24.
Garraud O, Perraut R, Riveau G, Nutman TB. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol. 2003;19(7):300–4.CrossRefPubMed
25.
Noranate N, Prugnolle F, Jouin H, Tall A, Marrama L, Sokhna C, et al. Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting. BMC Microbiol. 2009;9:219.CrossRefPubMedCentralPubMed
26.
Muller S. Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development. Int Rev Immunol. 2004;23(5-6):423–36.CrossRefPubMed
27.
Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526(2):159–66.CrossRefPubMed
28.
Diallo TO, Spiegel A, Diouf A, Lochouarn L, Kaslow DC, Tall A, et al. Short report: differential evolution of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients. Am J Trop Med Hyg. 2002;66(2):137–9.PubMed
29.
Garraud O, Mahanty S, Perraut R. Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol. 2003;24(1):30–5.CrossRefPubMed
30.
Sjöval C, Zapf J, von Löhneysen L, Magorivska I, Biermann M, Janko C, et al. Altered glycosylation of complexed native IgG molecules is associated with disease activity of systematic lupus erythematosus. Lupus. 2015;24(6):569–581.
31.
Goulabchand R, Vincent T, Batteux F, Eliaou JF, Guilpain P. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev. 2014;13(7):742–50.CrossRefPubMed
32.
33.
Panda S, Ding JL. Natural antibodies bridge innate and adaptive antibodies. J Immunol. 2015;194(1):13–20.CrossRefPubMed
34.
Jacobs JF, van dern Molen RG, Bossuyt X, Damoiseaux J. Antigen excess in modern immunoassay: to anticipate on the unexpected. Autoimmun Review. 2015;14(2):160–7.CrossRef
35.
Luchavez J, Baker J, Alcantara S, Belizario Jr V, McCarty JS, Bell D. Laboratory demonstration of a prozone-like effect in HRP-2-detecting malaria rapid diagnostic tests: implication for clinical management. Malar J. 2011;10:286.CrossRefPubMedCentralPubMed
36.
Chia WN, Goh YS, Renia L. Novel approaches to identify malaria vaccine candidates. Front Microbiol. 2014;17:586.
Metadata
Title
Immunogenicity of infectious pathogens and vaccine antigens
Authors
Siddhartha Mahanty
Antoine Prigent
Olivier Garraud
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2015
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-015-0095-y

Other articles of this Issue 1/2015

BMC Immunology 1/2015 Go to the issue

Research article

Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)

Research article

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis

Research article

PHF11 expression and cellular distribution is regulated by the Toll-Like Receptor 3 Ligand Polyinosinic:Polycytidylic Acid in HaCaT keratinocytes

Research article

The effect of immunological status, in-vitro treatment and culture time on expression of eleven candidate reference genes in bovine blood mononuclear cells

Research article

Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients

Research article

Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits